Skip to main content
OpenTrials
Completed

NCT Number: NCT01930435

Study of Personalized Sterile Humidification Device for Mucositis in Head and Neck Cancer Patients

This is a single arm study of the use of a personalized sterile humidification device for 12 weeks for head and neck cancer patients undergoing radiation therapy to determine if the usage of this humidification system will result in a decrease in severity in head and neck related quality of life as measured by the MDASI HN subscale following radiation therapy as compared with historical experience. In addition, we are exploring correlative measures using CRP, IL-1, IL-6, and TNF-alpha level measurements as these are directly related to mucositis and presumably related to quality of life as indicated by the patient.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Head and Neck Cancer Head and Neck Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Helen Diller Family Comprehensive Center, UCSF

San Francisco, California, 94115, United States

About this study

The patients complete MDASI at baseline, 6 weeks, and 12 weeks. The MDASI is a validated instrument that measures symptom burden and we measure a subscale (HN) as our primary endpoint. The patients are asked to use a personal humidifier daily and complete a weekly diary showing compliance with the humidifier use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Receiving a dose of radiation therapy greater than or equal to 6000 cGy to one third of the oral cavity.
  • Receiving definitive or post-operative adjuvant radiotherapy.
  • Receiving radiotherapy or chemoradiation.
  • Of age greater than 18 years.
  • Life expectancy greater than 6 months.
  • Able to provide informed consent.
  • Participation of patients on other clinical trial protocols permitted, if not prohibited by trial guidelines.

Exclusion criteria

  • Undergoing induction or neoadjuvant chemotherapy prior to radiotherapy.
  • Treatment with amifostine or palifermin (keratinocyte growth factor) during radiotherapy.
  • High risk for poor compliance with radiotherapy, humidification, or follow-up as assessed by the investigator.

Treatment and study plan

Sterile Humidification Device

Device

This is a personal humidification device. It is hand held and produces sterile warm vapor.

Other names: MyPurMist

Primary outcomes

  1. Mean Change in Quality of Life as Measured by the Subscale MDASI-HN Score.

    Time frame: Mean value of [(MDASI-HN score at 6 weeks) - (MDASI-HN score at baseline)]

    The MDASI-HN assesses the severity of symptoms at their worst in the last 24 hours on a 0-10 NRS, with 0 being "not present" and 10 being "as bad as you can imagine." There are 28 items in the MDASI-HN. There are 13 general inventory items, 6 general interference items, and the HN subscale adds 9 additional items assessing mucus in the mouth and throat, difficulty swallowing/chewing, choking/coughing, difficulty with voice/speech, skin pain/burning/rash, constipation, problems with tasting food, mouth/throat sores, and problems with teeth or gums. Scores for the subscales (general, interference, HN) are averaged so that a score is obtained from 0-10 for each subscale. The mean change in quality of life is calculated as the average scores at 6 weeks minus the average of the scores at baseline. Therefore a positive value represents a worsened quality of life and a negative value is an improvement in quality of life.

Secondary outcomes

  1. Percentage of Patients Achieving Compliance With Use of Personalized Sterile Humidification.

    Time frame: over entire 12 weeks duration

    Compliance was pre-specified in the protocol as self-reported usage of the device at a level equal to or greater than 60% of the formal recommended usage. This cut-off at 60% represented the median of the distribution of the usage of the device among all patients. The outcome measure is the percentage of participants who reported using the device at a level equal to or greater than 60% of the total prescribed usage.

  2. Clinician Graded CTCAE-rated Mucositis Score Over 12 Weeks

    Time frame: over 12 weeks duration

    The maximum severity of clinician rating of mucositis observed over 12 weeks, as graded on a scale ranging from 1 (minimal mucositis) to 3 (confluent mucositis) to 5 (death) using the Common Terminology Criteria for Adverse Events v 4.0

  3. Rate of Feeding Tube Placement Among Patients Using Personalized Sterile Humidification

    Time frame: over 12 weeks duration

    Feeding Tube Placement in Patients Who Use Personalized Sterile Humidification, as determined by placement of either nasogastric or gastrostomy tube. This was enumerated as the number of participants who had a feeding tube placed.

  4. Rate of Hospitalization in Patients Who Use Personalized Sterile Humidification

    Time frame: during 12 weeks duration

    Rate of Hospitalization in Patients Who Use Personalized Sterile Humidification, determined based on admission to hospital over active study period

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Official study title

A Phase II Study Monitoring Quality of Life and Correlative Biomarkers of Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy Utilizing a Personalized Sterile Humidification Device

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Aug 29, 2013
Registry last updated
Aug 10, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.